Article info
PDFA difficult case
Late-onset cobalamin C disease: rare but treatable
- Correspondence to Dr Rajesh K Singh, Neurology, AIIMS, New Delhi 110029, India; drrajeshrims679{at}gmail.com
Citation
Late-onset cobalamin C disease: rare but treatable
Publication history
- Accepted May 31, 2022
- First published July 8, 2022.
Online issue publication
October 18, 2023
Article Versions
- Previous version (16 November 2022).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- Homocystinuria diagnosis and management: it is not all classical
- Complementation studies in the cblAclass of inborn error of cobalamin metabolism: evidence for interallelic complementation and for a new complementation class (cblH)
- Neurological outcome of methylmalonic acidaemia
- Report of rapid diagnosis and precise management of MMADHC-related intracellular cobalamin defect
- The adolescent and adult form of cobalamin C disease: clinical and molecular spectrum
- Clinical analysis of late-onset methylmalonic acidaemia and homocystinuria, cblC type with a neuropsychiatric presentation
- Homocystinuria: a commentary
- Combined malonic and methylmalonic aciduria: exome sequencing reveals mutations in the ACSF3 gene in patients with a non-classic phenotype
- Evaluation of the clinical, biochemical, genotype and prognosis of mut-type methylmalonic acidemia in 365 Chinese cases
- Hereditary selective cobalamin malabsorption and concurrent pancreatitis in a young Border collie